• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ionis Pharmaceuticals (NQ: IONS )

    38.46 -0.58 (-1.49%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Ionis Pharmaceuticals

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    A Glimpse Into The Expert Outlook On Ionis Pharmaceuticals Through 5 Analysts
    Via Benzinga
    Where Ionis Pharmaceuticals Stands With Analysts
    Via Benzinga
    Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
    The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
    Via Benzinga
    Topics ETFs Stocks
    Exposures US Equities
    Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
    The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
    Via Investor's Business Daily
    New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
    From Biogen Inc.
    Via GlobeNewswire
    Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (13 Ratings)
    Via Benzinga
    Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    What 14 Analyst Ratings Have To Say About Ionis Pharmaceuticals
    Via Benzinga
    12 Analysts Have This To Say About Ionis Pharmaceuticals
    Via Benzinga
    Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
    From Biogen Inc.
    Via GlobeNewswire
    Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
    Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... 
    Via Benzinga
    Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
    Biogen previously decided against opting into Ionis' Angelman program. 
    Via Investor's Business Daily
    The Latest Analyst Ratings For Ionis Pharmaceuticals
    Via Benzinga
    Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
    Via Benzinga
    Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
    Via Benzinga
    The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals
    Via Benzinga
    RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    Masters In Trading - Saturday, June 22
    In this video, I discuss a stock that is expected to see major upside, and I take a closer look at my portfolio. 
    Via Talk Markets
    Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile
    Discover the results of Ionis Pharmaceuticals' Phase 3 studies on donidalorsen for hereditary angioedema. FDA application submission expected this year. 
    Via Benzinga
    Exposures Product Safety
    Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
    The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-approved treatment targeting the genetic cause of ALS. 
    Via Benzinga
    Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
    Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes. 
    Via Benzinga
    The Latest Analyst Ratings For Ionis Pharmaceuticals
    Via Benzinga
    Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
    From Biogen Inc.
    Via GlobeNewswire
    The 3 Most Undervalued Pharma Stocks to Buy in May 2024
    Investors looking for good deals in the pharmaceutical industry should watch out for these three undervalued pharma stocks. 
    Via InvestorPlace
    IONS Stock Earnings: Ionis Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
    IONS stock results show that Ionis Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows
    Ionis Pharmaceuticals reports positive Phase 2 results for ION224, showing significant improvement in MASH and liver histology without worsening fibrosis. Safe and well-tolerated treatment with... 
    Via Benzinga
    Are These 5 Undervalued Stocks Ready to Break Out?
    Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices. 
    Via MarketBeat
    New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
    From Biogen Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.